Treatment options in hormone resistant prostate cancer

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 95-102

  De Mulder, P H M ^a   Schalken, J A ^b   Sternberg, C N ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Foundation Vincenzo Pansodoro   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BCG VACCINE; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETOPOSIDE; FLUTAMIDE; GESTAGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; SURAMIN; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INJECTION SITE; LEUKOPENIA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; STATISTICAL ANALYSIS; UNITED STATES;

EID: 0036434671     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf645     Document Type: Article

References (67)

1. Jermal A, Thomas A, Murray F et al. American Cancer Society. Prostate Cancer 2002. Cancer Statistics 2002. CA Cancer J Clin 2002; 52: 23.
2. Jhaveri F, Kleine E, Kupelian P et al. Declining rates of extra capsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999; 17: 3167-3172.
3. Bonkhoff H, Remberger K. Differentiation pathways and histogenic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996; 2: 33-50.
4. van Leenders G, Aalders T, Hulsbergen van de Kaa C et al. Expression of basal keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195: 563-570.
5. Schalken J, Visakorpi T, Thalmann G et al. Molecular biology for urologists. Eur Urol 2001; 39: (Curric Urol 7.2) 1-11.
6. Palmberg C, Koivisto P, Kakkola L et al. Androgen receptor gene amplification at the time of primary progression predicts response to combined androgen blockade as a second-line therapy in advanced prostate cancer. J Urol 2000; 164: 1992-1995.
7. Trachtenberg J, Pont A. Ketocenazole therapy for advanced prostate cancer. Lancet 1984; 2: 433-435.
8. Tannock I, Gospodarowicz M, Meakin W et al. Treatment of metastatic prostate cancer with low dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-597.
9. Geller J, Albert J. Adrenal androgen blockade in relapsed prostate cancer. Eur J Cancer Clin Oncol 1985; 21: 1127-1131.
10. Fossa SD, Hosbach G, Paus E. Flutamide in hormone resistant prostatic cancer. J Urol 1990; 144: 1411-1414.
11. Droz JP, Kattan J, Bonnay M et al. High dose continuous infusion fosfestrol in hormone resistant prostate cancer. Cancer 1992; 71: 1123-1128.
12. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997; 15: 13-19.
13. Sasagawa I, Satoni S. Effects of high dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer. Br J Urol 1990; 65: 278-281.
14. Scher HI, Kelly WK. The flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostatic cancer. J Clin Oncol 1993; 11: 1566-1572.
15. Leo ME, Bilhartz DL, Bergstralh EJ et al. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991; 145: 802-806.
16. Newling D, Dennis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 1993; 72 (Suppl.): 3793-3799.
17. Scher HI, Curley T, Geller N et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate specific antigen and acid phosphatase as a marker in measurable hormone refractory disease. J Clin Oncol 1990; 8: 1830-1838.
18. Dawson NA. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 1998; 16: 3398-3405.
19. Kelly WK, Scher HI, Mazumdar M et al. Prostate specific antigen as a measure of disease outcome in hormone refractory prostatic cancer. J Clin Oncol 1993; 11: 607-615.
20. Fossa SD, Paus E. Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report. Eur Urol 1994; 26: 29-34.
21. Bubley G, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: recommendations from the prostate specific antigen working group. J Clin Oncol 1999; 17: 3461-3467.
22. Eisenberger MA, Simon R, O'Dwyer PJ, et al. A re-evaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827-841.
23. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993; 71 (Suppl. 3): 1098-1109.
24. Sternberg CN. Systemic treatment and new developments in advanced prostate cancer. Eur J Cancer 2001; 37 (Suppl. 7): S147S-S157.
25. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
26. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol l999; 17: 2506-2513.
27. Hudes G. Estramustine based chemotherapy. Semin Urol Oncol 1997; 15: 13-19.
28. Hudes GR, Greenberg R, Krigel RL et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992; 10: 1754-1761.
29. Seidman AD, Scher HI, Petrylak D et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial endpoint in hormone-refractory prostatic cancer. J Urol 1992; 147: 931-934.
30. Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17: 3160-3166.
31. Albrecht W, Horenblas S, Marechal JM et al. A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy versus estramustine alone in patients with hormone escaped progressive metastatic prostate cancer. Eur Urol 1998; 33 (Suppl. 1): 47 (Abstr 187).
32. Hudes G, Nathan F, Khater C et al. Phase II trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-3163.
33. Kelly K, Gaudin P, Slovin S et al. Paclitaxel (T), estramustine (E) and carboplatin (C) in patients with advanced prostate cancer (PC). J Urol 1999; 161: 683 (Abstr).
34. Petrylak D, Macarthur R, O'Connor J et al. Phase I trial of docetaxel with estarmustine in androgen independent prostate cancer. J Clin Oncol 1999; 17: 958-967.
35. Kreis W, Budman DR, Fetten J et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10: 33-38.
36. Savarese D, Halabi S, Hars V et al. A phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report CALGB 9780. J Clin Oncol 2001; 19: 2509-2515.
37. Sinibaldi VJ, Carducci MA, Moore-Cooper S et al. A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in patients (pts) with hormone refractory prostate cancer (HRPC): Updated preliminary analysis. Proc Am Soc Clin Oncol 2000; 19: 346a (Abstr 1361).
38. Trivedi C, Redman B, Flaherty LE et al. Weekly 1-hour infusion of clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000; 89: 431-436.
39. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer (HRPC). Proc Am Soc Clin Oncol 2000; 19: 348a (Abstr 1368).
40. Leitner SP, Scoppetuelo M, Kanowitz JM et al. Phase II trial of weekly one hour paclitaxel (T) plus oral estramustine (E) taken the day before, of, and after paclitaxel in patients (pts) with metastatic hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1999; 18: 345a (Abstr 1331).
41. Hudes GR, Manola J, Conroy J et al. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 2001; 20: 175a (Abstr 697).
42. Berry W, Gregurich M, Dakhil S et al. Phase II randomized trial of weekly paclitaxel (Taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP). Proc Am Soc Clin Oncol 2001; 20: 175a (Abstr).
43. Kamradt JM, Smith DC, Pienta KJ. Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience. Urol Clin North Am 1999; 26: 333-340.
44. Raghavan D, Cox K, Pearson BS et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993; 72: 625-628.
45. Smith DC, Esper P, Strawderman M et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17: 1664-1671.
46. George DJ, Kantoff PW. Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 1999; 26: 303-310.
47. Rini BI, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep 2001; 3: 418-423.
48. Harris DT, Matyas GR, Gomella LG et al. Immunologic approaches to the treatment of prostate cancer. Semin Oncol 1999; 26: 439-447.
49. Murphy G, Tjoa B, Radge H et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201 specific peptides from prostate specific membrane antigen. Prostate 1996; 29: 371-380.
50. Murphy G, Tjoa B, Simmons S et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39: 54-59.
51. Simons JW, Mikhak B, Chang JF et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
52. Small EJ, Reese DM, Um B et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5: 1738-1744.
53. Dreicer R, See WA, Klein E. Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 2001; 19: 261-265.
54. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
55. Weidner N, Carroll P, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
56. Duque JL, Loughlin KR, Adam RM et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523-527.
57. Slamon DJ, Leyland-Jones B, Shack S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
58. Karashima T, Sweeney P, Slaton JW et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8: 1253-1264.
59. Hellawell GO, Turner GD, Davies DR et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-2950.
60. Kuhn E, Kurnot R, Sesterhenn I et al. Expression of the c-erb-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993; 150: 1427-1433.
61. Stein C. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer 1993; 53: 2239-2248.
62. Eisenberger M, Sinibaldi V, Reyno L et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone refractory prostate cancer. J Clin Oncol 1995; 13: 2174-2186.
63. Small E, Meyer M, Marshall M et al. Suramin therapy for patients with symptomatic hormone refractory prostate cancer: results of a randomised phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18: 1140-1145.
64. Morris MJ, Tong WP, Cordon-Cardo C et al. BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer. Eur J Cancer 2001; 37 (Suppl. 6): S218.
65. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28 (4 Suppl. 15): 67-70.
66. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
67. Harrington K, Spitzweg C, Bateman A et al. Gene therapy for prostate cancer: current status and future prospects. J Urol 2001; 166: 1220-1233.